24/7 Market News Snapshot 21 February, 2025 – ACELYRIN, INC. Common Stock (NASDAQ:SLRN)

February 21, 2025

DENVER, Colo., 21 February, 2025 (247marketnews.com) – (NASDAQ:SLRN) are discussed in this article.
Acelyrin, Inc. (SLRN) is experiencing notable fluctuations in its stock performance, recently trading at $2.425, a decrease of approximately 11.75% from its prior close of $2.170. This decline comes amidst heightened trading volume at 4.94 million shares, indicating substantial investor activity. The stock’s journey also highlights potential resistance at $2.55, with critical support expected around $2.17, prompting investors to closely observe these levels for making strategic decisions.

In a significant development, Acelyrin has received an unsolicited acquisition proposal from Concentra Biosciences, LLC, offering $3.00 per share for all outstanding shares. This proposal includes a contingent value right that would see shareholders entitled to 80% of net proceeds from any licensing or sale of the company’s development programs and intellectual property. This unsolicited offer comes on the heels of Acelyrin’s planned all-stock merger with Alumis Inc. (Nasdaq:ALMS), scheduled to close in the second quarter of 2025, pending shareholder and regulatory approvals.

The Board of Directors at Acelyrin is committed to acting in the best interests of its shareholders and intends to thoroughly review this acquisition proposal in the context of the existing merger agreement with Alumis. Investors have been advised that no immediate action is required on their part, as the Board evaluates the situation. Financial advisory services are being provided by Guggenheim Securities, LLC, with legal counsel from Fenwick & West LLP and Paul Hastings LLP.

As Acelyrin remains dedicated to developing innovative therapies—particularly its lead program, lonigutamab, designed to treat thyroid eye disease—the company is focused on communicating further updates as they arise, ensuring stakeholders are informed throughout this critical period.

Related news for (SLRN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.